

David E Cohn

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3849701/publications.pdf>

Version: 2024-02-01

280
papers

15,142
citations

17440
63
h-index

22832
112
g-index

284
all docs

284
docs citations

284
times ranked

15183
citing authors

#	ARTICLE	IF	CITATIONS
1	Who will be readmitted? Evaluation of the laparoscopic hysterectomy readmission score in a gynecologic oncology population undergoing robotic-assisted hysterectomy. <i>Gynecologic Oncology</i> , 2022, 164, 628-638.	1.4	4
2	More than treatment refusal: a National Cancer Database analysis of adjuvant treatment refusal and racial survival disparities among women with endometrial cancer. <i>American Journal of Obstetrics and Gynecology</i> , 2022, 227, 244.e1-244.e17.	1.3	8
3	Pembrolizumab with or without bevacizumab for recurrent or metastatic cervical cancer: A cost-effectiveness analysis. <i>Gynecologic Oncology</i> , 2022, 165, 500-505.	1.4	6
4	Less is more: Abdominal closure protocol does not reduce surgical site infection after hysterectomy. <i>Gynecologic Oncology</i> , 2022, 166, 69-75.	1.4	1
5	Oncolytic HSV Therapy Modulates Vesicular Trafficking Inducing Cisplatin Sensitivity and Antitumor Immunity. <i>Clinical Cancer Research</i> , 2021, 27, 542-553.	7.0	14
6	Double somatic mismatch repair gene pathogenic variants as common as Lynch syndrome among endometrial cancer patients. <i>Gynecologic Oncology</i> , 2021, 160, 161-168.	1.4	24
7	Endometrial Cancer: Who Lives, Who Dies, Can We Improve Their Story?. <i>Oncologist</i> , 2021, 26, 1044-1051.	3.7	7
8	NCCN Guidelines® Insights: Uterine Neoplasms, Version 3.2021. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 888-895.	4.9	113
9	Lenvatinib plus pembrolizumab in advanced recurrent endometrial cancer: A cost-effectiveness analysis. <i>Gynecologic Oncology</i> , 2021, 162, 626-630.	1.4	11
10	Phase I evaluation of lenvatinib and weekly paclitaxel in patients with recurrent endometrial, ovarian, fallopian tube, or primary peritoneal Cancer. <i>Gynecologic Oncology</i> , 2021, 162, 619-625.	1.4	7
11	Prehabilitation for medically frail patients undergoing surgery for epithelial ovarian cancer: a cost-effectiveness analysis. <i>Journal of Gynecologic Oncology</i> , 2021, 32, e92.	2.2	18
12	Wound complications following vulvar excision for nonmalignant lesions. <i>AJOG Global Reports</i> , 2021, 1, 100022.	1.0	1
13	Up-Front Multigene Panel Testing for Cancer Susceptibility in Patients With Newly Diagnosed Endometrial Cancer: A Multicenter Prospective Study. <i>JCO Precision Oncology</i> , 2021, 5, 1588-1602.	3.0	15
14	Aberrant expression of TMEM205 signaling promotes platinum resistance in ovarian cancer: An implication for the antitumor potential of DAP compound. <i>Gynecologic Oncology</i> , 2021, , .	1.4	3
15	Preoperative predictors of endometrial cancer at time of hysterectomy for endometrial intraepithelial neoplasia or complex atypical hyperplasia. <i>American Journal of Obstetrics and Gynecology</i> , 2020, 222, 60.e1-60.e7.	1.3	58
16	Risk-Reducing Salpingo-Oophorectomy and Breast Cancer Risk Reduction in the Gynecologic Oncology Group Protocol-0199 (GOG-0199). <i>JNCI Cancer Spectrum</i> , 2020, 4, pkz075.	2.9	11
17	Guideline-concordant endometrial cancer treatment and survival in the Women's Health Initiative Life and Longevity After Cancer study. <i>International Journal of Cancer</i> , 2020, 147, 404-412.	5.1	9
18	Society of gynecologic oncology future of physician payment reform task force: Lessons learned in developing and implementing surgical alternative payment models. <i>Gynecologic Oncology</i> , 2020, 156, 701-709.	1.4	3

#	ARTICLE	IF	CITATIONS
19	Prospective follow-up of quality of life for participants undergoing risk-reducing salpingo-oophorectomy or ovarian cancer screening in GOG-0199: An NRG Oncology/GOG study. <i>Gynecologic Oncology</i> , 2020, 156, 131-139.	1.4	8
20	Fertilityâ€sparing surgery and survival among reproductiveâ€age women with epithelial ovarian cancer in 2 cancer registries. <i>Cancer</i> , 2020, 126, 1217-1224.	4.1	26
21	Carboplatin and Paclitaxel for Advanced Endometrial Cancer: Final Overall Survival and Adverse Event Analysis of a Phase III Trial (NRG Oncology/GOG0209). <i>Journal of Clinical Oncology</i> , 2020, 38, 3841-3850.	1.6	155
22	Evaluating the efficacy of enzalutamide and the development of resistance in a preclinical mouse model of type-I endometrial carcinoma. <i>Neoplasia</i> , 2020, 22, 484-496.	5.3	7
23	Niraparib maintenance in frontline management of ovarian cancer: a cost effectiveness analysis. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 1569-1575.	2.5	10
24	Patient reported outcomes measures in gynecologic oncology: A primer for clinical use, part I. <i>Gynecologic Oncology</i> , 2020, 158, 194-200.	1.4	9
25	Is hormonal therapy after risk-reducing salpingo-oophorectomy associated with an increased risk of malignancy in pathogenic variant carriers?. <i>Gynecologic Oncology</i> , 2020, 157, 706-710.	1.4	0
26	Patient reported outcomes measures in gynecologic oncology: A primer for clinical use, Part II. <i>Gynecologic Oncology</i> , 2020, 158, 201-207.	1.4	5
27	NCCN Guidelines Insights: Cervical Cancer, Version 1.2020. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 660-666.	4.9	189
28	Inherited alterations of TGF beta signaling components in Appalachian cervical cancers. <i>Cancer Causes and Control</i> , 2019, 30, 1087-1100.	1.8	6
29	Secondary Surgical Cytoreduction for Recurrent Ovarian Cancer. <i>New England Journal of Medicine</i> , 2019, 381, 1929-1939.	27.0	217
30	Intentional weight loss, weight cycling, and endometrial cancer risk: a systematic review and meta-analysis. <i>International Journal of Gynecological Cancer</i> , 2019, 29, 1361-1371.	2.5	26
31	Cervical Cancer, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 64-84.	4.9	700
32	A Microfluidic Chip Enables Isolation of Exosomes and Establishment of Their Protein Profiles and Associated Signaling Pathways in Ovarian Cancer. <i>Cancer Research</i> , 2019, 79, 3503-3513.	0.9	72
33	Randomized Trial of Intravenous Versus Intraperitoneal Chemotherapy Plus Bevacizumab in Advanced Ovarian Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study. <i>Journal of Clinical Oncology</i> , 2019, 37, 1380-1390.	1.6	178
34	Inhibition of miR-328â€3p Impairs Cancer Stem Cell Function and Prevents Metastasis in Ovarian Cancer. <i>Cancer Research</i> , 2019, 79, 2314-2326.	0.9	68
35	Sustained release paclitaxel-loaded core-shell-structured solid lipid microparticles for intraperitoneal chemotherapy of ovarian cancer. <i>Artificial Cells, Nanomedicine and Biotechnology</i> , 2019, 47, 957-967.	2.8	26
36	Engineered multifunctional biodegradable hybrid microparticles for paclitaxel delivery in cancer therapy. <i>Materials Science and Engineering C</i> , 2019, 102, 113-123.	7.3	23

#	ARTICLE	IF	CITATIONS
37	Targeted composite value-based endpoints in platinum-sensitive recurrent ovarian cancer. <i>Gynecologic Oncology</i> , 2019, 152, 445-451.	1.4	3
38	Prospective clinical trial of robotic sentinel lymph node assessment with isosulfane blue (ISB) and indocyanine green (ICG) in endometrial cancer and the impact of ultrastaging (NCT01818739). <i>Gynecologic Oncology</i> , 2019, 153, 496-499.	1.4	50
39	The prognostic significance of aortic lymph node metastasis in endometrial cancer: Potential implications for selective aortic lymph node assessment. <i>Gynecologic Oncology</i> , 2019, 153, 505-510.	1.4	24
40	The association between histological subtype of a first primary endometrial cancer and second cancer risk. <i>International Journal of Gynecological Cancer</i> , 2019, 29, 290-298.	2.5	5
41	Conization pathologic features as a predictor of intermediate and high risk features on radical hysterectomy specimens in early stage cervical cancer. <i>Gynecologic Oncology</i> , 2019, 153, 255-258.	1.4	10
42	Mismatch repair deficiency identifies patients with highâ€œintermediateâ€œ risk (HIR) endometrioid endometrial cancer at the highest risk of recurrence: A prognostic biomarker. <i>Cancer</i> , 2019, 125, 398-405.	4.1	35
43	Outpatient desensitization of patients with moderate (high-risk) to severe platinum hypersensitivity reactions. <i>Gynecologic Oncology</i> , 2019, 152, 316-321.	1.4	27
44	Gestational Trophoblastic Neoplasia, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 1374-1391.	4.9	86
45	Hypoxia-induced exosomes contribute to a more aggressive and chemoresistant ovarian cancer phenotype: a novel mechanism linking STAT3/Rab proteins. <i>Oncogene</i> , 2018, 37, 3806-3821.	5.9	215
46	Uterine Neoplasms, Version 1.2018, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018, 16, 170-199.	4.9	488
47	Cancer care delivery research in gynecologic oncology. <i>Gynecologic Oncology</i> , 2018, 148, 445-448.	1.4	2
48	<i>STAT3/PIAS3</i> Levels Serve as â€œEarly Signatureâ€œ Genes in the Development of High-Grade Serous Carcinoma from the Fallopian Tube. <i>Cancer Research</i> , 2018, 78, 1739-1750.	0.9	18
49	Is it reasonable to administer pegfilgrastim on day 1 of a myelosuppressive chemotherapy regimen? A cost-utility analysis. <i>Cancer Treatment and Research Communications</i> , 2018, 14, 21-25.	1.7	3
50	MAX Mutations in Endometrial Cancer: Clinicopathologic Associations and Recurrent MAX p.His28Arg Functional Characterization. <i>Journal of the National Cancer Institute</i> , 2018, 110, 517-526.	6.3	9
51	Society of Gynecologic Oncology Future of Physician Payment Reform Task Force report: The Endometrial Cancer Alternative Payment Model (ECAP). <i>Gynecologic Oncology</i> , 2018, 149, 232-240.	1.4	8
52	Recruiting Endometrial Cancer Survivors to Studies Examining Lifestyle Behaviors and Quality of Life: Challenges Faced and Lessons Learned. <i>Journal of Cancer Education</i> , 2018, 33, 857-864.	1.3	5
53	Role of Minimally Invasive Surgery in Gynecologic Malignancies. , 2018, , 560-578.e11.		1
54	An NRG Oncology/GOG study of molecular classification for risk prediction in endometrioid endometrial cancer. <i>Gynecologic Oncology</i> , 2018, 148, 174-180.	1.4	83

#	ARTICLE	IF	CITATIONS
55	Receipt of adjuvant endometrial cancer treatment according to race: anÂNRG Oncology/Gynecologic Oncology Group 210 Study. American Journal of Obstetrics and Gynecology, 2018, 219, 459.e1-459.e11.	1.3	12
56	Hyperthermic intraperitoneal chemotherapy (HIPEC) is cost-effective in the management of primary ovarian cancer. Gynecologic Oncology, 2018, 151, 4-5.	1.4	7
57	Detection of endometrial cancer cells in the fallopian tube lumen is associated with adverse prognostic factors and reduced survival. Gynecologic Oncology, 2018, 150, 38-43.	1.4	9
58	Functional characterization of recurrent <i>FOXA2</i> mutations seen in endometrial cancers. International Journal of Cancer, 2018, 143, 2955-2961.	5.1	6
59	Elevated STAT3 expression in ovarian cancer ascites promotes invasion and metastasis: a potential therapeutic target. Oncogene, 2017, 36, 168-181.	5.9	99
60	HDAC10 as a potential therapeutic target in ovarian cancer. Gynecologic Oncology, 2017, 144, 613-620.	1.4	39
61	Recurrent low grade serous ovarian cancer in a 20 year old woman: A case from the Ohio State University College of Medicine. Gynecologic Oncology, 2017, 144, 451-455.	1.4	2
62	Factors associated with deciding between risk-reducing salpingo-oophorectomy and ovarian cancer screening among high-risk women enrolled in GOG-0199: An NRG Oncology/Gynecologic Oncology Group study. Gynecologic Oncology, 2017, 145, 122-129.	1.4	21
63	Outpatient desensitization in selected patients with platinum hypersensitivity reactions. Gynecologic Oncology, 2017, 145, 603-610.	1.4	20
64	Vulvar Cancer, Version 1.2017, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2017, 15, 92-120.	4.9	136
65	The Microcystic, Elongated, and Fragmented (MELF) Pattern of Invasion. American Journal of Surgical Pathology, 2017, 41, 49-55.	3.7	44
66	Cost-effectiveness of opportunistic salpingectomy for ovarian cancer prevention. Gynecologic Oncology, 2017, 146, 373-379.	1.4	45
67	The "value" of value in gynecologic oncology practice in the United States: Society of Gynecologic Oncology evidence-based review and recommendations. Gynecologic Oncology, 2017, 145, 185-191.	1.4	4
68	Dose Dense Chemotherapy for Front-line Ovarian Cancer Treatment: The Price is Right?. Gynecologic Oncology, 2017, 145, 1-2.	1.4	2
69	Bokhman Redux: Endometrial cancer "types" in the 21st century. Gynecologic Oncology, 2017, 144, 243-249.	1.4	113
70	Nonsteroidal Anti-inflammatory Drugs and Endometrial Carcinoma Mortality and Recurrence. Journal of the National Cancer Institute, 2017, 109, djw251.	6.3	28
71	Reproductive counseling, contraception, and unplanned pregnancy in fertile women treated by gynecologic oncologists. Gynecologic Oncology Reports, 2017, 19, 22-26.	0.6	6
72	Primum non nocere : Are we ready for POLE testing in endometrial cancer?. Gynecologic Oncology, 2017, 147, 240-242.	1.4	7

#	ARTICLE	IF	CITATIONS
73	Cardiovascular disease mortality among women with endometrial cancer in the Iowa Women's Health Study. <i>Cancer Causes and Control</i> , 2017, 28, 1043-1051.	1.8	11
74	Epigenetic silencing of MLH1 in endometrial cancers is associated with larger tumor volume, increased rate of lymph node positivity and reduced recurrence-free survival. <i>Gynecologic Oncology</i> , 2017, 146, 588-595.	1.4	77
75	Randomized phase IIB evaluation of weekly paclitaxel versus weekly paclitaxel with oncolytic reovirus (Reolysin®) in recurrent ovarian, tubal, or peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , 2017, 146, 477-483.	1.4	50
76	Factors Associated With Deciding Between Risk-Reducing Salpingo-oophorectomy and Ovarian Cancer Screening Among High-Risk Women Enrolled in GOG-0199: An NRG Oncology/Gynecologic Oncology Group Study. <i>Obstetrical and Gynecological Survey</i> , 2017, 72, 336-337.	0.4	1
77	Genetic consultation embedded in a gynecologic oncology clinic improves compliance with guideline-based care. <i>Gynecologic Oncology</i> , 2017, 147, 110-114.	1.4	46
78	Targeting STAT3 by HO3867 induces apoptosis in ovarian clear cell carcinoma. <i>International Journal of Cancer</i> , 2017, 141, 1856-1866.	5.1	25
79	Race-specific molecular alterations correlate with differential outcomes for black and white endometrioid endometrial cancer patients. <i>Cancer</i> , 2017, 123, 4004-4012.	4.1	25
80	A Mindfulness-Based Lifestyle Intervention for Obese, Inactive Endometrial Cancer Survivors: A Feasibility Study. <i>Integrative Cancer Therapies</i> , 2017, 16, 263-275.	2.0	13
81	High cardiovascular disease mortality after endometrial cancer diagnosis: Results from the Surveillance, Epidemiology, and End Results (SEER) Database. <i>International Journal of Cancer</i> , 2017, 140, 555-564.	5.1	77
82	Less radical surgery for early-stage cervical cancer: Can conization specimens help identify patients at low risk for parametrial involvement?. <i>Gynecologic Oncology</i> , 2017, 144, 290-293.	1.4	13
83	High Glucose-Mediated STAT3 Activation in Endometrial Cancer Is Inhibited by Metformin: Therapeutic Implications for Endometrial Cancer. <i>PLoS ONE</i> , 2017, 12, e0170318.	2.5	30
84	Cost Comparison of Genetic Testing Strategies in Women With Epithelial Ovarian Cancer. <i>Journal of Oncology Practice</i> , 2017, 13, e120-e129.	2.5	11
85	ASCO Value Framework Highlights the Relative Value of Treatment Options in Ovarian Cancer. <i>Journal of Oncology Practice</i> , 2017, 13, e1030-e1039.	2.5	10
86	Novel <i>SOX17</i> frameshift mutations in endometrial cancer are functionally distinct from recurrent missense mutations. <i>Oncotarget</i> , 2017, 8, 68758-68768.	1.8	15
87	Fine-Scale Mapping at 9p22.2 Identifies Candidate Causal Variants That Modify Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. <i>PLoS ONE</i> , 2016, 11, e0158801.	2.5	10
88	Risk Factors for Readmission in Patients With Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma Who Are Receiving Front-line Chemotherapy on a Clinical Trial (GOG 218). <i>Obstetrical and Gynecological Survey</i> , 2016, 71, 24-26.	0.4	0
89	Aspirin and endometrial cancer risk. <i>Gynecologic Oncology Reports</i> , 2016, 17, 1-2.	0.6	5
90	The biological significance and clinical applications of exosomes in ovarian cancer. <i>Gynecologic Oncology</i> , 2016, 142, 199-205.	1.4	66

#	ARTICLE	IF	CITATIONS
91	MonoSeq Variant Caller Reveals Novel Mononucleotide Run Indel Mutations in Tumors with Defective DNA Mismatch Repair. <i>Human Mutation</i> , 2016, 37, 1004-1012.	2.5	6
92	Anticancer potential of diarylidenyl piperidone derivatives, HO-4200 and H-4318, in cisplatin resistant primary ovarian cancer. <i>Cancer Biology and Therapy</i> , 2016, 17, 1107-1115.	3.4	15
93	Use of CA-125 Tests and Computed Tomographic Scans for Surveillance in Ovarian Cancer. <i>JAMA Oncology</i> , 2016, 2, 1427.	7.1	45
94	Does time interval between surgery and intraperitoneal chemotherapy administration in advanced ovarian cancer carry a prognostic impact? An NRG Oncology/Gynecologic Oncology Group study ancillary study. <i>Gynecologic Oncology</i> , 2016, 143, 484-489.	1.4	6
95	Perioperative Outcomes for Laparotomy Compared to Robotic Surgical Staging of Endometrial Cancer in the Elderly: A Retrospective Cohort. <i>International Journal of Gynecological Cancer</i> , 2016, 26, 1717-1721.	2.5	26
96	Use of CA-125 Tests and Computed Tomographic Scans for Surveillance in Ovarian Cancer. <i>Obstetrical and Gynecological Survey</i> , 2016, 71, 660-661.	0.4	3
97	Clinicopathologic Significance of Mismatch Repair Defects in Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group Study. <i>Journal of Clinical Oncology</i> , 2016, 34, 3062-3068.	1.6	141
98	Frequent PIK3CA Mutations in Colorectal and Endometrial Tumors With 2 or More Somatic Mutations in Mismatch Repair Genes. <i>Gastroenterology</i> , 2016, 151, 440-447.e1.	1.3	36
99	Treatment strategies for stage IB cervical cancer: A cost-effectiveness analysis from Korean, Canadian and US perspectives. <i>Gynecologic Oncology</i> , 2016, 140, 83-89.	1.4	8
100	Prognostic Significance of POLE Exonuclease Domain Mutations in High-Grade Endometrioid Endometrial Cancer on Survival and Recurrence: A Subanalysis. <i>International Journal of Gynecological Cancer</i> , 2016, 26, 933-938.	2.5	38
101	Survival outcomes of obese patients in type II endometrial cancer: Defining the prognostic impact of increasing BMI. <i>Gynecologic Oncology</i> , 2016, 140, 405-408.	1.4	9
102	A Prospective, Comparative Study for the Evaluation of Postoperative Pain and Quality of Recovery in Patients Undergoing Robotic Versus Open Hysterectomy for Staging of Endometrial Cancer. <i>Journal of Minimally Invasive Gynecology</i> , 2016, 23, 429-434.	0.6	17
103	Estrogen receptor-alpha as a predictive biomarker in endometrioid endometrial cancer. <i>Gynecologic Oncology</i> , 2016, 141, 312-317.	1.4	75
104	Documentation of Pregnancy Risk Assessment and Pregnancy Among Women Presenting for Gynecologic Oncology Consultation. <i>International Journal of Gynecological Cancer</i> , 2016, 26, 35-42.	2.5	6
105	Endometrial Cancer Insulin-Like Growth Factor 1 Receptor (IGF1R) Expression Increases with Body Mass Index and Is Associated with Pathologic Extent and Prognosis. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2016, 25, 438-445.	2.5	15
106	Ultrasound mediated destruction of multifunctional microbubbles for image guided delivery of oxygen and drugs. <i>Ultrasonics Sonochemistry</i> , 2016, 28, 31-38.	8.2	37
107	The cost implications of the use of pegylated liposomal doxorubicin when choosing an anthracycline for the treatment of platinum-resistant ovarian cancer: A low-value intervention?. <i>Gynecologic Oncology Reports</i> , 2015, 13, 47-48.	0.6	4
108	Uterine Sarcoma, Version 1.2016. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015, 13, 1321-1331.	4.9	58

#	ARTICLE	IF	CITATIONS
109	Cervical Cancer, Version 2.2015. Journal of the National Comprehensive Cancer Network: JNCCN, 2015, 13, 395-404.	4.9	250
110	Robotic Hysterectomy for Endometrial Cancer in Obese Patients With Comorbidities: Evaluating Postoperative Complications. International Journal of Gynecological Cancer, 2015, 25, 1271-1276.	2.5	18
111	Evaluation of the Hematologic Safety of Same Day Versus Standard Administration (24- to 72-Hour) Tj ETQq1 1 0.784314 rgBT /Overl International Journal of Gynecological Cancer, 2015, 25, 1331-1336.	2.5	15
112	The Use of Transvaginal Ultrasound in Type II Endometrial Cancer. International Journal of Gynecological Cancer, 2015, 25, 858-862.	2.5	14
113	A cost-utility analysis of NRG Oncology/Gynecologic Oncology Group Protocol 218: Incorporating prospectively collected quality-of-life scores in an economic model of treatment of ovarian cancer. Gynecologic Oncology, 2015, 136, 293-299.	1.4	24
114	Lymphatic mapping and sentinel lymph node dissection compared to complete lymphadenectomy in the management of early-stage vulvar cancer: A cost-utility analysis. Gynecologic Oncology, 2015, 136, 300-304.	1.4	34
115	Predicting Inpatient Stay Lasting 2 Midnights or Longer After Robotic Surgery for Endometrial Cancer. Journal of Minimally Invasive Gynecology, 2015, 22, 583-589.	0.6	7
116	Bariatric surgery as a means to decrease mortality in women with type I endometrial cancer – An intriguing option in a population at risk for dying of complications of metabolic syndrome. Gynecologic Oncology, 2015, 138, 597-602.	1.4	14
117	Setting the bar: compliance with ovarian cancer quality indicators at a National Cancer Institute-designated Comprehensive Cancer Center. Gynecologic Oncology, 2015, 138, 689-693.	1.4	9
118	Long-chain 3 fatty acid intake and endometrial cancer risk in the Women's Health Initiative. American Journal of Clinical Nutrition, 2015, 101, 824-834.	4.7	17
119	Consensus in controversy: The modified Delphi method applied to Gynecologic Oncology practice. Gynecologic Oncology, 2015, 138, 712-716.	1.4	3
120	WWP2 and its association with PTEN in endometrial cancer. Gynecologic Oncology Reports, 2015, 13, 26-29.	0.6	16
121	Use and Effectiveness of Intraperitoneal Chemotherapy for Treatment of Ovarian Cancer. Journal of Clinical Oncology, 2015, 33, 2841-2847.	1.6	159
122	Relationships of Tubal Ligation to Endometrial Carcinoma Stage and Mortality in the NRG Oncology/Gynecologic Oncology Group 210 Trial. Journal of the National Cancer Institute, 2015, 107, .	6.3	32
123	Patterns of CTCF and ZFX3 Mutation and Associated Outcomes in Endometrial Cancer. Journal of the National Cancer Institute, 2015, 107, djv249.	6.3	37
124	Noncatalytic PTEN missense mutation predisposes to organ-selective cancer development in vivo. Genes and Development, 2015, 29, 1707-1720.	5.9	29
125	Associations between etiologic factors and mortality after endometrial cancer diagnosis: The NRG Oncology/Gynecologic Oncology Group 210 trial. Gynecologic Oncology, 2015, 139, 70-76.	1.4	23
126	Risk factors for readmission in patients with ovarian, fallopian tube, and primary peritoneal carcinoma who are receiving front-line chemotherapy on a clinical trial (GOG 218): an NRG oncology/gynecologic oncology group study (ADS-1236). Gynecologic Oncology, 2015, 139, 221-227.	1.4	20

#	ARTICLE	IF	CITATIONS
127	Combined Microsatellite Instability, <i>MLH1</i> Methylation Analysis, and Immunohistochemistry for Lynch Syndrome Screening in Endometrial Cancers From GOG210: An NRG Oncology and Gynecologic Oncology Group Study. <i>Journal of Clinical Oncology</i> , 2015, 33, 4301-4308.	1.6	163
128	Polymerase ϵ (<i>POLE</i>) mutations in endometrial cancer: Clinical outcomes and implications for Lynch syndrome testing. <i>Cancer</i> , 2015, 121, 386-394.	4.1	142
129	Surgery or chemoradiation for stage IB cervical cancer? How cost effectiveness impacts a complex decision. <i>Journal of Gynecologic Oncology</i> , 2014, 25, 79.	2.2	4
130	Outpatient rapid 4-step desensitization for gynecologic oncology patients with mild to low-risk, moderate hypersensitivity reactions to carboplatin/cisplatin. <i>Gynecologic Oncology</i> , 2014, 135, 90-94.	1.4	22
131	Does intra-operative radiation at the time of pelvic exenteration improve survival for patients with recurrent, previously irradiated cervical, vaginal, or vulvar cancer?. <i>Gynecologic Oncology</i> , 2014, 135, 95-99.	1.4	25
132	High Frequency Strand Slippage Mutations in <i>CTCF</i> in MSI-Positive Endometrial Cancers. <i>Human Mutation</i> , 2014, 35, 63-65.	2.5	28
133	Aberrantly activated pSTAT3-Ser727 in human endometrial cancer is suppressed by HO-3867, a novel STAT3 inhibitor. <i>Gynecologic Oncology</i> , 2014, 135, 133-141.	1.4	20
134	Associations of long-chain ω -3 fatty acids and fish intake with endometrial cancer risk in the VITamins And Lifestyle cohort. <i>American Journal of Clinical Nutrition</i> , 2014, 99, 599-608.	4.7	24
135	The cost-effectiveness of selective lymphadenectomy based on a preoperative prediction model in patients with endometrial cancer: Insights from the US and Korean healthcare systems. <i>Gynecologic Oncology</i> , 2014, 135, 518-524.	1.4	11
136	Comprehensive evaluation of caspase-14 in vulvar neoplasia: An opportunity for treatment with black raspberry extract. <i>Gynecologic Oncology</i> , 2014, 135, 503-509.	1.4	3
137	Feasibility of Interval Cytoreduction Following Neoadjuvant Chemotherapy With Carboplatin, Weekly Paclitaxel, and Bevacizumab for Advanced Ovarian Cancer—A Phase 1 Study. <i>International Journal of Gynecological Cancer</i> , 2014, 24, 682-686.	2.5	16
138	HO-3867, a Safe STAT3 Inhibitor, Is Selectively Cytotoxic to Ovarian Cancer. <i>Cancer Research</i> , 2014, 74, 2316-2327.	0.9	71
139	Phase III Randomized Trial of Weekly Cisplatin and Irradiation Versus Cisplatin and Tirapazamine and Irradiation in Stages IB2, IIA, IIB, IIIB, and IVA Cervical Carcinoma Limited to the Pelvis: A Gynecologic Oncology Group Study. <i>Journal of Clinical Oncology</i> , 2014, 32, 458-464.	1.6	102
140	Is bariatric surgery an option for women with gynecologic cancer? Examining weight loss counseling practices and training among gynecologic oncology providers. <i>Gynecologic Oncology</i> , 2014, 134, 540-545.	1.4	25
141	Options for repair of rectus abdominis myocutaneous perineal/vaginal flap prolapse: A case series. <i>Gynecologic Oncology Case Reports</i> , 2014, 7, 1-3.	0.9	5
142	Mismatch repair protein expression in 1049 endometrial carcinomas, associations with body mass index, and other clinicopathologic variables. <i>Gynecologic Oncology</i> , 2014, 133, 43-47.	1.4	35
143	A phase II study of gemcitabine, carboplatin and bevacizumab for the treatment of platinum-sensitive recurrent ovarian cancer. <i>Gynecologic Oncology</i> , 2014, 134, 262-266.	1.4	16
144	Uterine Neoplasms, Version 1.2014. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014, 12, 248-280.	4.9	113

#	ARTICLE	IF	CITATIONS
145	Targeting constitutively-activated STAT3 in hypoxic ovarian cancer, using a novel STAT3 inhibitor. <i>Oncoscience</i> , 2014, 1, 216-228.	2.2	33
146	Evaluation of the hematologic safety of same day versus standard administration of pegfilgrastim in gynecology oncology patients undergoing platinum-based chemotherapy.. <i>Journal of Clinical Oncology</i> , 2014, 32, 5569-5569.	1.6	0
147	Cost effectiveness of alternative strategies for incorporating bevacizumab into the primary treatment of ovarian cancer. <i>Cancer</i> , 2013, 119, 3653-3661.	4.1	42
148	Safe and targeted anticancer therapy for ovarian cancer using a novel class of curcumin analogs. <i>Journal of Ovarian Research</i> , 2013, 6, 35.	3.0	20
149	Assessment of FANCD2 nuclear foci formation in paraffin-embedded tumors: a potential patient-enrichment strategy for treatment with DNA interstrand crosslinking agents. <i>Translational Research</i> , 2013, 161, 156-164.	5.0	21
150	Phase II trial of combination bevacizumab and temsirolimus in the treatment of recurrent or persistent endometrial carcinoma: A Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , 2013, 129, 22-27.	1.4	140
151	Multicenter phase II trial of topotecan, cisplatin and bevacizumab for recurrent or persistent cervical cancer. <i>Gynecologic Oncology</i> , 2013, 130, 64-68.	1.4	73
152	Etiologic heterogeneity in endometrial cancer: Evidence from a Gynecologic Oncology Group trial. <i>Gynecologic Oncology</i> , 2013, 129, 277-284.	1.4	185
153	Non-steroidal anti-inflammatory drugs and endometrial cancer risk in the VITamins And Lifestyle (VITAL) cohort. <i>Gynecologic Oncology</i> , 2013, 128, 113-119.	1.4	29
154	The impact of close surgical margins after radical hysterectomy for early-stage cervical cancer. <i>Gynecologic Oncology</i> , 2013, 128, 44-48.	1.4	37
155	Complications after double-barreled wet colostomy compared to separate urinary and fecal diversion during pelvic exenteration: Time to change back?. <i>Gynecologic Oncology</i> , 2013, 128, 60-64.	1.4	27
156	Neuroendocrine carcinoma of the uterine cervix: The role of multimodality therapy in early-stage disease. <i>Gynecologic Oncology</i> , 2013, 129, 135-139.	1.4	28
157	Reporting of quality measures in gynecologic oncology programs at Prospective Payment System (PPS)-Exempt Cancer Hospitals: An early glimpse into a challenging initiative. <i>Gynecologic Oncology</i> , 2013, 130, 403-406.	1.4	11
158	Reducing readmissions after robotic surgical management of endometrial cancer:A potential for improved quality care. <i>Gynecologic Oncology</i> , 2013, 131, 508-511.	1.4	20
159	Comparison of methods to estimate health state utilities for ovarian cancer using quality of life data: A Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , 2013, 128, 175-180.	1.4	12
160	Analysis of disease recurrence and survival for women with uterine malignancies undergoing robotic surgery. <i>Gynecologic Oncology</i> , 2013, 128, 309-315.	1.4	44
161	Genome-Wide Association Study in BRCA1 Mutation Carriers Identifies Novel Loci Associated with Breast and Ovarian Cancer Risk. <i>PLoS Genetics</i> , 2013, 9, e1003212.	3.5	244
162	Should Bevacizumab Be Continued After Progression on Bevacizumab in Recurrent Ovarian Cancer?. <i>International Journal of Gynecological Cancer</i> , 2013, 23, 833-838.	2.5	7

#	ARTICLE	IF	CITATIONS
163	A Nonsynonymous Polymorphism in <i>IRS1</i> Modifies Risk of Developing Breast and Ovarian Cancers in <i>BRCA1</i> and Ovarian Cancer in <i>BRCA2</i> Mutation Carriers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2012, 21, 1362-1370.	2.5	23
164	HO-3867, a STAT3 inhibitor induces apoptosis by inactivation of STAT3 activity in <i>BRCA1</i> -mutated ovarian cancer cells. <i>Cancer Biology and Therapy</i> , 2012, 13, 766-775.	3.4	39
165	Performance of PREMM1,2,6, MMRpredict, and MMRpro in detecting Lynch syndrome among endometrial cancer cases. <i>Genetics in Medicine</i> , 2012, 14, 670-680.	2.4	40
166	Reovirus-associated reduction of microRNA-let-7d is related to the increased apoptotic death of cancer cells in clinical samples. <i>Modern Pathology</i> , 2012, 25, 1333-1344.	5.5	48
167	Role of Minimally Invasive Surgery in Gynecologic Malignancies. , 2012, , 631-649.e9.		1
168	A multi-institutional cohort study of adjuvant therapy in stage I-II uterine carcinosarcoma. <i>Gynecologic Oncology</i> , 2012, 127, 22-26.	1.4	94
169	Recurrent ovarian cancer: Is there a role for re-treatment with bevacizumab after an initial complete response to a bevacizumab-containing regimen?. <i>Gynecologic Oncology</i> , 2012, 127, 362-366.	1.4	9
170	Primary radiation therapy for medically inoperable patients with clinical stage I and II endometrial carcinoma. <i>Gynecologic Oncology</i> , 2012, 124, 36-41.	1.4	61
171	Short- and long-term morbidity and outcomes after robotic surgery for comprehensive endometrial cancer staging. <i>Gynecologic Oncology</i> , 2012, 125, 546-551.	1.4	64
172	Economic impact of paclitaxel shortage in patients with newly diagnosed ovarian cancer. <i>Gynecologic Oncology</i> , 2012, 125, 631-634.	1.4	25
173	Minimally invasive surgery versus laparotomy in women with high grade endometrial cancer: A multi-site study performed at high volume cancer centers. <i>Gynecologic Oncology</i> , 2012, 126, 180-185.	1.4	97
174	Common variants at 12p11, 12q24, 9p21, 9q31.2 and in <i>ZNF365</i> are associated with breast cancer risk for <i>BRCA1</i> and/or <i>BRCA2</i> mutation carriers. <i>Breast Cancer Research</i> , 2012, 14, R33.	5.0	78
175	Pathologic findings at risk-reducing salpingo-oophorectomy among women at increased ovarian cancer risk: Results from GOG-199.. <i>Journal of Clinical Oncology</i> , 2012, 30, 1519-1519.	1.6	8
176	Neuroendocrine carcinoma of the cervix: A single institution's experience.. <i>Journal of Clinical Oncology</i> , 2012, 30, e15585-e15585.	1.6	0
177	Phase II trial of topotecan, cisplatin, and bevacizumab for recurrent or persistent cervical cancer.. <i>Journal of Clinical Oncology</i> , 2012, 30, 5101-5101.	1.6	0
178	At What Cost Does a Potential Survival Advantage of Bevacizumab Make Sense for the Primary Treatment of Ovarian Cancer? A Cost-Effectiveness Analysis. <i>Journal of Clinical Oncology</i> , 2011, 29, 1247-1251.	1.6	152
179	Addition of bevacizumab to weekly paclitaxel significantly improves progression-free survival in heavily pretreated recurrent epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2011, 121, 269-272.	1.4	49
180	A randomized phase III trial of IV carboplatin and paclitaxel – 3 courses followed by observation versus weekly maintenance low-dose paclitaxel in patients with early-stage ovarian carcinoma: A Gynecologic Oncology Group Study. <i>Gynecologic Oncology</i> , 2011, 122, 89-94.	1.4	62

#	ARTICLE	IF	CITATIONS
181	What does cost have to do with it?. <i>Gynecologic Oncology</i> , 2011, 122, 465-466.	1.4	0
182	A black raspberry extract inhibits proliferation and regulates apoptosis in cervical cancer cells. <i>Gynecologic Oncology</i> , 2011, 123, 401-406.	1.4	43
183	Endometrial cancer patients and compliance with genetic counseling: Room for improvement. <i>Gynecologic Oncology</i> , 2011, 123, 532-536.	1.4	40
184	Activity of Sorafenib in Recurrent Ovarian Cancer and Primary Peritoneal Carcinomatosis: A Gynecologic Oncology Group Trial. <i>Journal of Clinical Oncology</i> , 2011, 29, 69-75.	1.6	165
185	Lynch Syndrome. <i>Clinical Obstetrics and Gynecology</i> , 2011, 54, 199-214.	1.1	31
186	Consistency of In Vitro Chemoresponse Assay Results and Population Clinical Response Rates Among Women With Endometrial Carcinoma. <i>International Journal of Gynecological Cancer</i> , 2011, 21, 494-499.	2.5	8
187	Large Prospective Study of Ovarian Cancer Screening in High-Risk Women: CA125 Cut-Point Defined by Menopausal Status. <i>Cancer Prevention Research</i> , 2011, 4, 1401-1408.	1.5	53
188	Temporary Extracorporeal Circulatory Support and Pulmonary Embolectomy for Catastrophic Amniotic Fluid Embolism. <i>Heart Surgery Forum</i> , 2011, 14, 157.	0.5	7
189	Comprehensive miRNA profiling of surgically staged endometrial cancer. <i>American Journal of Obstetrics and Gynecology</i> , 2010, 202, 656.e1-656.e8.	1.3	77
190	Lymphadenectomy for endometrial cancer: The controversy. <i>Gynecologic Oncology</i> , 2010, 117, 6-8.	1.4	61
191	Mismatch repair status and outcomes after adjuvant therapy in patients with surgically staged endometrial cancer. <i>Gynecologic Oncology</i> , 2010, 117, 234-238.	1.4	46
192	The prognostic significance of the triple negative phenotype in endometrial cancer. <i>Gynecologic Oncology</i> , 2010, 118, 172-175.	1.4	11
193	SGO White Paper on Ovarian Cancer: Etiology, Screening and Surveillance. <i>Gynecologic Oncology</i> , 2010, 119, 7-17.	1.4	139
194	Immunization with synthetic VEGF peptides in ovarian cancer. <i>Gynecologic Oncology</i> , 2010, 119, 564-570.	1.4	30
195	Corrigendum to "Combination gemcitabine, platinum, and bevacizumab for the treatment of recurrent ovarian cancer" [<i>Gynecologic Oncology</i> 111 (2008) 461-466]. <i>Gynecologic Oncology</i> , 2010, 119, 603.	1.4	0
196	Health-related quality of life outcomes associated with four cisplatin-based doublet chemotherapy regimens for stage IVB recurrent or persistent cervical cancer: A Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , 2010, 119, 531-537.	1.4	36
197	A COG 210 aCGH study of gain at 1q23 in endometrioid endometrial cancer in the context of racial disparity and outcome. <i>Genes Chromosomes and Cancer</i> , 2010, 49, 791-802.	2.8	12
198	REO-10: A Phase I Study of Intravenous Reovirus and Docetaxel in Patients with Advanced Cancer. <i>Clinical Cancer Research</i> , 2010, 16, 5564-5572.	7.0	120

#	ARTICLE	IF	CITATIONS
199	Robotic Pelvic and Aortic Lymphadenectomy for Endometrial Cancer: The Console Surgeon's Perspectives on Surgical Technique and Directing the Assistant. Journal of Minimally Invasive Gynecology, 2010, 17, 180-185.	0.6	12
200	Abstract 2594: Reovirus replication in ovarian and peritoneal tumors after intravenous administration. Cancer Research, 2010, 70, 2594-2594.	0.9	7
201	Minimally invasive surgery. , 2010, , 235-249.		0
202	Phase III Trial of Four Cisplatin-Containing Doublet Combinations in Stage IVB, Recurrent, or Persistent Cervical Carcinoma: A Gynecologic Oncology Group Study. Journal of Clinical Oncology, 2009, 27, 4649-4655.	1.6	576
203	Role of lymphadenectomy in the staging of endometrial cancer. Nature Reviews Clinical Oncology, 2009, 6, 382-384.	27.6	2
204	The detection of differentially expressed microRNAs from the serum of ovarian cancer patients using a novel real-time PCR platform. Gynecologic Oncology, 2009, 112, 55-59.	1.4	597
205	Prospective evaluation of prognostic significance of the tumor-free distance from uterine serosa in surgically staged endometrial adenocarcinoma. Gynecologic Oncology, 2009, 112, 146-149.	1.4	21
206	Sequential chemotherapy and irradiation in advanced stage endometrial cancer: A Gynecologic Oncology Group phase I trial of doxorubicin+ cisplatin followed by whole abdomen irradiation. Gynecologic Oncology, 2009, 112, 553-557.	1.4	17
207	Minimally invasive comprehensive surgical staging for endometrial cancer: Robotics or laparoscopy?. Gynecologic Oncology, 2009, 113, 36-41.	1.4	242
208	Current and emerging trends in Lynch syndrome identification in women with endometrial cancer. Gynecologic Oncology, 2009, 114, 128-134.	1.4	97
209	A detailed analysis of the learning curve: Robotic hysterectomy and pelvic-aortic lymphadenectomy for endometrial cancer. Gynecologic Oncology, 2009, 114, 162-167.	1.4	144
210	Multicenter analysis of recurrence and survival in stage IIIA endometrial cancer. Gynecologic Oncology, 2009, 114, 279-283.	1.4	24
211	Prospective evaluation of DNA mismatch repair protein expression in primary endometrial cancer. Gynecologic Oncology, 2009, 114, 486-490.	1.4	68
212	A multicenter evaluation of sequential multimodality therapy and clinical outcome for the treatment of advanced endometrial cancer. Gynecologic Oncology, 2009, 114, 442-447.	1.4	111
213	Are prediction models for Lynch syndrome valid for probands with endometrial cancer?. Familial Cancer, 2009, 8, 483-487.	1.9	14
214	Metastatic Squamous Cell Carcinoma of the Vulva to the Lung Confirmed With Allelotyping. International Journal of Gynecological Pathology, 2009, 28, 497-501.	1.4	6
215	Comprehensive Surgical Staging for Endometrial Cancer in Obese Patients. Obstetrics and Gynecology, 2009, 114, 16-21.	2.4	129
216	Lynch Syndrome Screening Strategies Among Newly Diagnosed Endometrial Cancer Patients. Obstetrics and Gynecology, 2009, 114, 530-536.	2.4	62

#	ARTICLE	IF	CITATIONS
217	Outpatient Platinum-Taxane Intraperitoneal Chemotherapy Regimen for Ovarian Cancer. International Journal of Gynecological Cancer, 2009, 19, 1195-1198.	2.5	9
218	Ovarian and Endometrial Cancer in Patients with Hereditary Non-polyposis Colorectal Cancer Syndrome. , 2009, , 163-181.		0
219	Robotic hysterectomy and lymphadenectomy for endometrial cancer: technical aspects and details of successâ€”the Ohio State University method. Journal of Robotic Surgery, 2008, 2, 71-76.	1.8	14
220	Panniculectomy concurrent with anterior pelvic exenteration for recurrent cervical cancer. Gynecologic Oncology, 2008, 108, 449-451.	1.4	6
221	Local correction of extreme stomal prolapse following transverse loop colostomy. Gynecologic Oncology, 2008, 111, 549-551.	1.4	17
222	Stage IV endometrial cancer after failed conservative management: A case report. Gynecologic Oncology, 2008, 111, 579-582.	1.4	22
223	Novel perioperative imaging with 18F-FDG PET/CT and intraoperative 18F-FDG detection using a handheld gamma probe in recurrent ovarian cancer. Gynecologic Oncology, 2008, 110, 152-157.	1.4	42
224	RE: Panniculectomy concurrent with anterior pelvic exenteration for recurrent cervical cancer. Gynecologic Oncology, 2008, 110, 269.	1.4	0
225	CA125 decline in ovarian cancer patients treated with intravenous versus intraperitoneal platinum-based chemotherapy. Gynecologic Oncology, 2008, 111, 233-236.	1.4	13
226	Combination gemcitabine, platinum, and bevacizumab for the treatment of recurrent ovarian cancer. Gynecologic Oncology, 2008, 111, 461-466.	1.4	52
227	Robotic Trocar Site Small Bowel Evisceration After Gynecologic Cancer Surgery. Obstetrics and Gynecology, 2008, 112, 462-464.	2.4	39
228	Robotic Hysterectomy and Pelvicâ€”Aortic Lymphadenectomy for Endometrial Cancer. Obstetrics and Gynecology, 2008, 112, 1207-1213.	2.4	116
229	Comment on: Screening for Lynch Syndrome (Hereditary Nonpolyposis Colorectal Cancer) among Endometrial Cancer Patients. Cancer Research, 2007, 67, 9603-9603.	0.9	88
230	Clinical and Pathologic Correlates in Surgical Stage II Endometrial Carcinoma. Obstetrics and Gynecology, 2007, 109, 1062-1067.	2.4	55
231	Profiling Microdissected Epithelium and Stroma to Model Genomic Signatures for Cervical Carcinogenesis Accommodating for Covariates. Cancer Research, 2007, 67, 7113-7123.	0.9	87
232	Neutralization of Endogenous Vascular Endothelial Growth Factor Depletes Primordial Follicles in the Mouse Ovary1. Biology of Reproduction, 2007, 76, 218-223.	2.7	37
233	Cost-Effectiveness Analysis of Strategies for the Surgical Management of Grade 1 Endometrial Adenocarcinoma. Obstetrics and Gynecology, 2007, 109, 1388-1395.	2.4	31
234	The Mucin Expression Profile of Endometrial Carcinoma and Correlation With Clinical-Pathologic Parameters. Applied Immunohistochemistry and Molecular Morphology, 2007, 15, 426-431.	1.2	18

#	ARTICLE	IF	CITATIONS
235	Cost-Effectiveness Analysis of Strategies for the Surgical Management of Grade 1 Endometrial Adenocarcinoma. <i>Obstetrics and Gynecology</i> , 2007, 110, 933-934.	2.4	0
236	Vaginal evisceration during intraperitoneal chemotherapy for advanced ovarian cancer. <i>Gynecologic Oncology</i> , 2007, 104, 491-493.	1.4	7
237	A multi-institutional review of outcomes of endometrial stromal sarcoma. <i>Gynecologic Oncology</i> , 2007, 105, 630-634.	1.4	187
238	A gynecologic oncology group randomized phase III trial of whole abdominal irradiation (WAI) vs. cisplatin-ifosfamide and mesna (CIM) as post-surgical therapy in stage IV carcinosarcoma (CS) of the uterus. <i>Gynecologic Oncology</i> , 2007, 107, 177-185.	1.4	257
239	Randomized trial results of quality of life comparing whole abdominal irradiation and combination chemotherapy in advanced endometrial carcinoma: A gynecologic oncology group study. <i>Quality of Life Research</i> , 2007, 16, 89-100.	3.1	49
240	HER-2 Is an Independent Prognostic Factor in Endometrial Cancer: Association With Outcome in a Large Cohort of Surgically Staged Patients. <i>Journal of Clinical Oncology</i> , 2006, 24, 2376-2385.	1.6	216
241	Screening for Lynch Syndrome (Hereditary Nonpolyposis Colorectal Cancer) among Endometrial Cancer Patients. <i>Cancer Research</i> , 2006, 66, 7810-7817.	0.9	564
242	Clinical Activity of Pertuzumab (rhuMAb 2C4), a HER Dimerization Inhibitor, in Advanced Ovarian Cancer: Potential Predictive Relationship With Tumor HER2 Activation Status. <i>Journal of Clinical Oncology</i> , 2006, 24, 4324-4332.	1.6	239
243	Improved Survival With an Intact DNA Mismatch Repair System in Endometrial Cancer. <i>Obstetrics and Gynecology</i> , 2006, 108, 1208-1215.	2.4	56
244	Efficacy and toxicity of the novel chemotherapeutic agent KW-2170 in recurrent epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2006, 102, 338-342.	1.4	5
245	Advanced endometrial cancer with serous metastasis in a 17-year-old. <i>Gynecologic Oncology</i> , 2006, 101, 356-359.	1.4	6
246	Bevacizumab and weekly taxane chemotherapy demonstrates activity in refractory ovarian cancer. <i>Gynecologic Oncology</i> , 2006, 102, 134-139.	1.4	91
247	Surgical Staging for Patients Presenting With Grade 1 Endometrial Carcinoma. <i>Obstetrics and Gynecology</i> , 2005, 105, 487-493.	2.4	144
248	Correlation of cyclooxygenase-2 (COX-2) and aromatase expression in human endometrial cancer: Tissue microarray analysis. <i>American Journal of Obstetrics and Gynecology</i> , 2005, 192, 1262-1271.	1.3	55
249	Evaluation of gemcitabine in previously treated patients with non-squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group. <i>Gynecologic Oncology</i> , 2005, 96, 103-107.	1.4	52
250	Invasive cervical adenocarcinoma immediately following a cone biopsy for adenocarcinoma in situ with negative margins. <i>Gynecologic Oncology</i> , 2005, 98, 158-160.	1.4	17
251	The role of MRI in the conservative management of endometrial cancer. <i>Gynecologic Oncology</i> , 2004, 93, 233-237.	1.4	44
252	Surgical pathological predictors of disease-free survival and risk groupings for IB2 cervical cancer: do the traditional models still apply?. <i>Gynecologic Oncology</i> , 2004, 94, 249-255.	1.4	29

#	ARTICLE	IF	CITATIONS
253	A comparison of stages IB1 and IB2 cervical cancers treated with radical hysterectomy. Is size the real difference?. Gynecologic Oncology, 2004, 95, 70-76.	1.4	45
254	Morbid obesity and endometrial cancer: surgical, clinical, and pathologic outcomes in surgically managed patients. Gynecologic Oncology, 2004, 95, 588-592.	1.4	87
255	Association between serum levels of soluble tumor necrosis factor receptors/CA 125 and disease progression in patients with epithelial ovarian malignancy. Cancer, 2004, 101, 106-115.	4.1	18
256	GM-CSF Induces Expression of Soluble VEGF Receptor-1 from Human Monocytes and Inhibits Angiogenesis in Mice. Immunity, 2004, 21, 831-842.	14.3	86
257	Gynecologic malignancies in adolescents. Adolescent Medicine Clinics, 2004, 15, 549-568.	0.8	20
258	Vaginal Reconstruction in Pelvic Exenteration. , 2004, , 663-673.		0
259	Pre-emptive analgesia in gynecologic surgical procedures: Preoperative wound infiltration with ropivacaine in patients who undergo laparotomy through a midline vertical incision. American Journal of Obstetrics and Gynecology, 2003, 188, 901-905.	1.3	23
260	Is there a prognostic difference between depth of myometrial invasion and the tumor-free distance from the uterine serosa in endometrial cancer?. Gynecologic Oncology, 2003, 91, 547-551.	1.4	31
261	Uterine papillary serous carcinoma: comparisons of outcomes in surgical Stage I patients with and without adjuvant therapy. Gynecologic Oncology, 2003, 91, 470-475.	1.4	131
262	Liquid-based cytology for the postirradiation surveillance of women with gynecologic malignancies. Gynecologic Oncology, 2003, 91, 134-138.	1.4	16
263	Ureteroileoneocystostomy: The Use of an Ileal Segment for Ureteral Substitution in Gynecologic Oncology. Gynecologic Oncology, 2002, 84, 110-114.	1.4	6
264	Use of Complementary and Alternative Medicine among Women with Gynecologic Cancers. Gynecologic Oncology, 2002, 84, 363-367.	1.4	102
265	Prospective Evaluation of Positron Emission Tomography for the Detection of Groin Node Metastases from Vulvar Cancer. Gynecologic Oncology, 2002, 85, 179-184.	1.4	162
266	Phase II Study of Mitomycin, Doxorubicin, and Cisplatin in the Treatment of Advanced Uterine Leiomyosarcoma: A Gynecologic Oncology Group Study. Gynecologic Oncology, 2002, 85, 507-510.	1.4	41
267	The Significance of Pneumatosis Intestinalis or Bowel Perforation in Patients with Gynecologic Malignancies. Gynecologic Oncology, 2002, 86, 79-84.	1.4	10
268	Outcome of Reproductive Age Women with Stage IA or IC Invasive Epithelial Ovarian Cancer Treated with Fertility-Sparing Therapy. Gynecologic Oncology, 2002, 87, 1-7.	1.4	257
269	Should the Presence of Lymphovascular Space Involvement Be Used to Assign Patients to Adjuvant Therapy Following Hysterectomy for Unstaged Endometrial Cancer?. Gynecologic Oncology, 2002, 87, 243-246.	1.4	113
270	Meigs? syndrome with an elevated CA 125 from benign Brenner tumors. Obstetrics and Gynecology, 2001, 98, 980-982.	2.4	21

#	ARTICLE	IF	CITATIONS
271	New Innovations in Cervical Cancer Screening. Clinical Obstetrics and Gynecology, 2001, 44, 538-549.	1.1	22
272	Genotypic and phenotypic progression in endometrial tumorigenesis: Determining when defects in DNA mismatch repair and KRAS2 occur. Genes Chromosomes and Cancer, 2001, 32, 295-301.	2.8	18
273	No evidence for BCL10 mutation in endometrial cancers with microsatellite instability. Human Mutation, 2001, 17, 117-121.	2.5	4
274	Factors Predicting Subcutaneous Implanted Central Venous Port Function: The Relationship between Catheter Tip Location and Port Failure in Patients with Gynecologic Malignancies. Gynecologic Oncology, 2001, 83, 533-536.	1.4	24
275	Gestational trophoblastic diseases: new standards for therapy. Current Opinion in Oncology, 2000, 12, 492-496.	2.4	15
276	Absence of PTEN Repeat Tract Mutation in Endometrial Cancers with Microsatellite Instability. Gynecologic Oncology, 2000, 79, 101-106.	1.4	27
277	Atypical Clustering of Gynecologic Malignancies: A Family Study Including Molecular Analysis of Candidate Genes. Gynecologic Oncology, 2000, 77, 18-25.	1.4	8
278	Mesothelial Pelvic Lymph Node Inclusions Mimicking Metastatic Thyroid Carcinoma. Gynecologic Oncology, 1998, 68, 210-213.	1.4	23
279	Adenocarcinoma of the uterine cervix metastatic to lymph nodes. American Journal of Obstetrics and Gynecology, 1998, 178, 1131-1137.	1.3	13
280	Intraperitoneal spread of cervical carcinoma after laparoscopic lymphadenectomy. Obstetrics and Gynecology, 1997, 89, 864.	2.4	37